CAS: 142825-10-3; (R)-1-Isothiocyanato-4-(Methylsulfinyl)Butane

上下游产品

CAS号4430-36-8 三芥子酸甘油酯 | CAS号52096-68-1 N-(4-methylsulf... | CAS号75-15-0 二硫化碳 | CAS号55021-77-7 4-(甲基硫代)-1-丁胺 | CAS号463-71-8 硫光气 | CAS号84104-30-3 (R)-4-(Methylsu...

(S)-4-(Tert-Butyldimethylsiloxy)Butyl Methyl Sulfoxide置于sodium Azide,氢氟酸,三乙胺,三苯基膦体系中,用 二氯甲烷,N,N-二甲基甲酰胺,乙腈 用作溶剂,化学反应 18.5H,反应生成L-萝卜硫素
参考文献:Asymmetric Synthesis Of Chiral Sulfinate Esters And Sulfoxides. Synthesis Of Sulforaphane
标题:Asymmetric Synthesis Of Chiral Sulfinate Esters And Sulfoxides. Synthesis Of Sulforaphane
摘要:Reaction Of The Chiral Auxiliary Trans-2-Phenylcyclohexanol (1) With Thionyl Chloride Afforded A Nearly Equal Mixture Of Two Diastereomeric Chlorosulfite Esters (6); Treatment Of This Mixture With An Equivalent Amount Of A Dialkylzinc Reagent (Me,Et,I-Pr) Afforded High Levels Of Conversion Of Both Chlorosulfite Esters To (Mainly) A Single Diastereomer Of The Sulfinate Ester (7). Levels Of Absolute Stereochemical Induction Ranged From 10:1 To 96:4 Under Conditions Affording High Chemical Yields. The Method Was Employed For The Separate Synthesis Of Both Enantiomers Of Sulforaphane (13).
Doi:10.1021/jo00082A016

专利信息

专利号:WO-2017046598-A1
优先权日:2015-09-16
标题:Treatment of acute inflammatory disorders
发明人：CRISANTI ANDREA; CANAVESE MIRIAM
权利人:CRISANTI ANDREA; IMP INNOVATIONS LTD
摘要:The present invention relates to a VEGF receptor agonist for use in the treatment of an acute inflammatory disorder associated with the overproduction of pro-inflammatory cytokine, administered with an agent that induces the synthesis of Nrf2. The invention also relates to pharmaceutical combinations comprising a VEGF receptor agonist and an agent that induces the synthesis of Nrf2, and kits comprising these agents. The described uses, combinations and methods may prevent or reduce the dis-regulated activation of an inflammatory response and reduce endothelial damage.

专利号:WO-2025069039-A1
优先权日:2023-09-28
标题:An in situ process for the preparation of primary amine compounds
发明人：SAMANT RAJARAM; TONGRA MANOJ
权利人:SAMANT RAJARAM; TONGRA MANOJ
摘要:An in situ process for the preparation of primary amine compounds The invention disclosed herein relates to an in situ process for the preparation of primary amine compounds. Particularly, it relates to the preparation of primary amine compounds having general Formula (I). Formula (I) wherein n is 1 to 9 and X is -S, -N- or -O. More particularly, the present invention relates to the preparation of primary amine compounds with high yield and purity which is further used as potent intermediate in the synthesis of therapeutically active isothiocyanates (ITCs).

专利号:US-9688611-B2
优先权日:2015-10-21
标 题:Synthesis of (S)-2-acetamido-3-(4-hydroxy-3-(3-methylbut-2-enyl) phenyl) propanoic acid derivatives
发明人：MANSHA Muhammad; ABBAS YASIR; ULLAH NISAR
权利人:UNIV KING FAHD PET & MINERALS
摘要:A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.

专利号:US-2014357576-A1
优先权日:2013-05-31
标题:Methods for enhancement of muscle protein synthesis
发明人：BREUILLE DENIS; STELLINGWERFF TRENT; MOORE DANIEL RYAN; OFFORD CAVIN ELIZABETH ANN; PHILLIPS STUART MARTIN
权利人:NESTEC SA
摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis by enhancing myofibrillar muscle protein synthesis. The method includes administering to the individual a mixed macronutrient composition having (i) an amount of whey protein that is not capable of enhancing myofibrillar protein synthesis when ingested by itself and (ii) free leucine. The composition comprises at least about 5.0 g total leucine per dose.

专利号:WO-2015040533-A1
优先权日:2013-09-19
标题:Methods for enhancing muscle protein synthesis during energy deficit
发明人：BAILEY DAVID MARK; ZALTAS ERIC SCOTT; STELLINGWERFF TRENT; MOORE DANIEL RYAN; HAWLEY JOHN ALAN; BURKE LOUISE MARY
权利人:PREMIER NUTRITION CORP
摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis during periods of negative energy balance, or energy deficit. The methods include administering to an individual suffering from energy deficit a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof. The methods also include administering to an individual suffering from energy deficit a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than doses typically recommended for individuals experiencing energy balance.

专利号:US-2014294788-A1
优先权日:2013-03-26
标 题 :Methods for enhancing muscle protein synthesis following concurrent training
发明人：BAILEY DAVID MARK; ZALTAS ERIC SCOTT; MOORE DANIEL RYAN; STELLINGWERFF TRENT
权利人:NESTEC SA
摘要:The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training.